Bionano Genomics | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 7.367 M

Revenue: As of FY2025 Q3, the actual value is USD 7.367 M, beating the estimate of USD 6.906 M.

EBIT: As of FY2025 Q3, the actual value is USD -8.806 M.

Segment Revenue

• Total revenue for Q3 2025 was $7.4 million, a 21% increase from $6.1 million in Q3 2024.
• Consumables and software revenues increased by 15%.
• Instrument revenue was $1.6 million in Q3 2025, compared to $1.4 million in Q3 2024.

Operational Metrics

• Gross margin for Q3 2025 was 46%, compared to -139% in Q3 2024.
• Non-GAAP gross margin was 46% in Q3 2025, up from 26% in Q3 2024.
• Operating expenses were reduced by 66% to $11.9 million, and non-GAAP operating expenses decreased by 40% to $9.7 million.
• Net loss for Q3 2025 was -$8.5 million, compared to -$44.2 million in Q3 2024.

Cash Flow

• Cash, cash equivalents, available-for-sale securities, and restricted short-term investments totaled $31.8 million at the end of Q3 2025.

Unique Metrics

• Sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase from 7,835 flowcells in Q3 2024.
• Installed base of OGM systems increased to 384, a 4% increase from 368 systems at the end of Q3 2024.

Outlook / Guidance

• Bionano anticipates full year 2025 revenue to be in the range of $26.0 to $30.0 million and Q4 2025 revenue to be between $7.5 to $7.9 million.
• The company expects new OGM system installations to surpass 25 for the full year 2025, exceeding prior expectations of 20 to 25.